Background: Parkinson's Disease (PD) is considered a chronic progressive neurodegenerative disorder and it can affect both motor and nonmotor functions. Around one million Americans have the disease and 1-3% of the individuals who are older than 60 years of age of the general population are affected worldwide. The progression of PD, from the first damage of the nervous system cells to the appearance of clinical symptoms, takes a considerable long period. Therefore, it is very important to identify the affected individuals before the appearance of the clinical manifestations to start protective strategies as early as possible. Objective: To evaluate Parkinson's disease, pathophysiology, symptomology, and management in the published and provide an adequate review tackling these topics. Method: PubMed database was used for article selection, and the following keys were used in the mesh ((“Parkinson Disease"[Mesh]) AND (“management”[Mesh]) OR (“evaluation"[Mesh])). Conclusion: The treatment of PD is symptoms-based and the medications are targeted toward the dopaminergic pathway. The most effective treatment for PD is levodopa. It treats most of the symptoms successfully. However, levodopa is associated with severe adverse effects. Therefore, other medications such as Monoamine Oxidase B (MAO-B) inhibitors and dopamine agonists can be started to delay the need for levodopa. A non-medical approach such as physical therapy and exercise is recommended along with medical therapy.
